
	Ý				COMPLETE IF KNOWN	
PE JC.				Application Number	09/982,259	
	INFORMATION	DISCLOSURE		Confirmation Number	8229	
D 184 5 8 2001	STATEMENT I	BY APPLICANT		Filing Date	October 17, 2001	
JAH	orm PTO-14			First Named Inventor	Qiu, Bo et al	·
1	e several she	ets if necessary	')	Group Art Unit	1645	
The same of				Examiner Name	Rodney Swartz	
Sheet	11	of	2	Attorney Docket No.	54114.8002.US00	

						J.S. PATENT	DOCUMENTS		
Examiner Initials	Cite No.		S. Patent or A	pplication Kind ((if kn	Code		tentee or inventor d Document	Date of Publication of Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear
	FOREIGN PATENT DOCUMENTS								
-		Fore	eign Patent or	Applica				Date of	_
Examiner Initial	Cite No.	Office	NUMBER	Ki	nd Code f known)		atentee or Applicanted Document	Publication o Filing Date t of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear T
								RE DOCUMENTS	riate), title of the item
Examiner Initials	Cite No					al, symposium, ca		age(s), volume issue	number(s), publisher, city
MA	C1	Re	BAR, Fritz W., et al., "New Biocompatible Polymer Surface Coating for Stents" VA D Results in a Low Neointimal Response," J. Biomedical Materials Respect, 2000; 52:193-198.						
	C2	Sta	BECKER, Timothy A., "Calcium Alginate Gel: A Biocompatible and Mechanically Stable Polymer for Endovascular Embolization," <i>J. Biomedical Materials Research</i> 2001; 54:76-86.						
	C3	1	BUCHKO, Christopher J. et al., "Surface Characterization of Porous, Biocompatible Protein Polymer Thin Films," <i>Biomaterials</i> 2001; 22:1289-1300.						
	C4		BURON, F., et al., "BOP: Biocompatible Osteoconductive Polymer: An Experimental Approach," Clinical Materials 1994; 16:217-221.						
	C5* ERSHOV, I.A., et al., "Polymer Biocompatible X-Ray Contract Hydrogel for Esophageal Vein Obstruction in Portal Hypertension," Med. Tekh. 1994; 2:37-40. (Russian. See translation of Findings attached to article.)								
	C6*	C6* HAISCH, A., et al., "Tissue Engineering of Human Cartilage for Reconstructive Surgery Using Biocompatible, Resorbable Fibrin Glue with Polymer Structures," HNO 1996; 44:624-629. (German. English abstract on p. 625.)							
	C7 ISOBE, Masatsugu <i>et al.</i> , "Bone Morphogenetic Protein Encapsulated with a Biodegradable and Biocompatible Polymer," <i>Journal of Biomedical Materials Research</i> 1996; 32:433-438.								
EXAMINER	30	Su	aut	-			DATE CONSIDERI	/	
*EXAMINE	R: Initi	al if refere	nce considered	d, whether	er or not o	riteria is in conform	nance with MPEP 609	. Draw line through cit	ation if not in conformance and not
25 44 44 0000		O# A0226				communication to	application(s).		

[54114-8002-US0000/LA033630.061]



	OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	Т					
M	C8	IWASAKI, Yasuhiko et al., "Semi-interpenetrating Polymer Networks composed of Biocompatible Phospholipid Polymer and Segmented Polyurethane," Journal of Biomedical Materials Research 2000; 52:701-708.						
<i>i</i> (C9	LANGER, R., "Biomaterials in Drug Delivery," <i>Accounts of Chemical Research</i> . Nov. 2, 2000; 33:94-101.						
	C10	LANGER, R., "Tissue Engineering," Molecular Therapy January 2000; 1:12-15.						
	C11*	POLOUS, Y. M., et al., "The Application of the Biocompatible Antimicrobic Polymer Film for the Prevention of Intestinal Suture Incompetence Under Conditions of Peritonitis," Vest. Khir. Im. II Grek 1985; 134:55-57. (Greek. English abstract on p. 57.)						
	C12	QIU, Bo et al., "Selection of Continuous Epitope Sequences and Their Incorporation into Poly(Ethylene Glycol)-Peptide Conjugates for Use in Serodiagnostic Immunoassays: Application to Lyme Disease," <i>Biopolymers</i> 2000; 55:319-333.						
Į.	C13	RAUDINO, Antonio <i>et al.</i> , "Binding of Lipid Vesicles to Protein-Coated Solid Polymer Surfaces: A Model for Cell Adhesion to Artificial Biocompatible Materials," <i>Journal of Colloid and Interface Science</i> 2000; 231:66-73.						

RECEIVED
FEB 0 5 2004
TECH CENTER 1600/2900

EXAMINED	PSwart	<u> </u>
		

DATE CONSIDERED

10-1-04

EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).

OIPE					COMPLETE IF KNOWN
1	LICODMATION	I DISCLOSURE		Application Number	09/982,259
AUG 2 7 2004	CINFORMATION CSTATEMENT E	DISCLOSURE		Confirmation Number	8229
				Filing Date	October 17, 2001
	The several sha	149 (Modified)		First Named Inventor	Bo Qiu
PADEMARKO	5/ Form PTO-14 (Use several she	ets if necessary)	Group Art Unit	1645
	1			Examiner Name	Rodney Swartz
Sheet	1	of	#3	Attorney Docket No.	54114.8002.US00

				·	U.S. PATENT DOCUMENTS			
Examin er Initials	Er Kind Code		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Line Where Relevant Figures Appear	es,		
0.0	C14	4,970,	300		Fulton	11/1990		
My	C15	5,187,	065		Schutzer	02/16/1993		
	C16	5,219,	564		Zalipsky	06/15/1993		
	C17	5,455,	027		Zalipsky	10/03/1995		
	C18	5,545,	698		Barany	08/13/1996		
				FC	REIGN PATENT DOCUMENTS			
Exami ner nitial	Cite No.	Foreign Patent or Application Cite Kind Code No. Office NUMBER (if known)		of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear	т	
	C19	WO 9	1 13630		United States of America	09/19/1991		
	C20	WO 97	7 42221		Statens Seruminstitut	11/13/1997		
			OTHER PRI	OR AR	RT-NON PATENT LITERATURE	DOCUMENTS		
Examiner Initials	Cite No	(000)	Include name of t k, magazine, jour	nal, seri	or (in CAPITAL LETTERS), title of the ar ial, symposium, catalog, etc.), date, pag and/or country where publish	e(s), volume issue num	e), title of the item nber(s), publisher, city	
	C21	BARB Science	OUR, "The ce 1610 (19	Biolo 93).	gical and Social Phenomer	non of Lyme Di	sease", 260	
	C22	Contai	BRUNNER, "Immune Complexes from Serum of Patients with Lyme Disease Contain Borrelia burgdorferi Antigen and Antigen-Specific Antibodies: Potential Use for Improved Testing", 182 J. of Infectious Diseases 534 (2000).					
	C23	BRUN Early L burgdo	BRUNNER, "Immunoglobulin M Capture Assay for Serologic Confirmation of Early Lyme Disease: Analysis of Immune Complexes with Biotinylated Borrelia burgdorferi Sonicate Enhanced with Flagellin Peptide Epitope", 36 J. Clin. Micro. 1074 (1998).					
	C24	Compi	BRUNNER, "New Method for Detection of Borrelia burgdorferi Antigen Complexed to Antibody in Seronegative Lyme Disease", 249 J. Immunol. Methods 185 (2001).					


EXAMINER	DATE CONSIDERED			
K Dwart	10-1-04			
*EXAMINER: Initial if reference considered, whether or not criteria is in conform considered. Include copy of this form with next communication to	mance with MPEP 609. Draw line through citation if not in conformance and not to application(s)			
tent to approach (%).				

[54114-8002-00000/LA042190.007]

						COMPLETE IF KNOWN
J	V016				Application Number	09/982,259
			DISCLOSURE		Confirmation Number	8229
$I \perp$	Alls 2 7 2004 9	STATEMENT B	T APPLICANT		Filing Date	October 17, 2001
国	was to tolky c	Form PTO-14	49 (Modified)		First Named Inventor	Bo Qiu
/3		øse several sne	ets if necessary)		Group Art Unit	1645
1	TANDELLAN OF				Examiner Name	Rodney Swartz
Į	Sheet	2	of	3	Attorney Docket No.	54114.8002.US00

	-	OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	т
W	C26	BUCKMANN, "Functionalization of Poly(ethylene glycol) and Monomethoxy-Poly(ethylene glycol)", 182 Makromol Chem. 1379 (1981).	
	C27	ERVIN, "The Bell Tolls for the Infectious Diseases Clinician", 153 J Inf Dis 183 (1986).	
	C28	FRANK, "Spot Synthesis: An Easy Technique for the Positionally Addressable, Parellel Chemical Synthesis on a Membrane Support", 48 Tetrahedron 9217 (1992).	
	C29	GECKELER, "Functionalization of Soluble Polymers", 1 Polym. Bull 427 (1979).	
	C30	GEYSEN, "Use of Peptide Synthesis to Probe Viral Antigens for Epitopes to a Resolution of a Single Amino Acid", 81 Proc. Natl. Acad. Sci. 3998 (1984).	
	C31	GILMORE, "Outer Surface Protein C (OspC), but not p39, is a Protective Immunogen Against a Tick-Transmitted Borrelia burgdorferi Challenge: Evidence for a Conformational Protective Epitope in OspC", 64 Infection and Immunity 2234 (1996).	
	C32	JUNGBLUT, "Proteomics in Human Disease: Cancer, Heart and Infectious Diseases", 20 Electrophoresis 2100 (1999).	
	C33	MAGNARELLI, "Cross Reactivity of Nonspecific Treponemal Antibody in Serologic Tests for Lyme Disease", 28 J. Clin. Microbiol. 1276 (1990).	
	C34	MATHIESEN, "The Dominant Epitope of Borrelia garinii Outer Surface Protein C Recognized by Sera from Patients with Neuroborreliosis Has a Surface-Exposed Conserved Structural Motif", 66 Inf. And Immun. 4073 (1998).	
	C35	MATHIESEN, "Peptide Based OspC Enzyme-Linked Immunosorbent Assay for Serodiagnosis of Lyme Borreliosis", 36 J. Clin. Microbiol. 3474 (1998).	
	C36	QIU, "Studies on Polymers for Biomedical Applications:", (Dissertation, Oct. 1999) (unpublished).	
	C37	SCHNEIDER, "Prognostic B-Cell Epitopes on the Flagellar Protein of Borrelia burgdorferi", 60 Inf and Immun. 316 (1992).	
	C38	SIGAL, "The Lyme Disease Controversy", 156 Arch. Intern. Med 1493 (1996).	

EXAMINER O Swart	DATE CONSIDERED (C-/-O-/
*EXAMINER: Initial if reference considered, whether or not criteria is in conformation to considered. Include copy of this form with next communication to	nance with MPEP 609. Draw line through citation if not in conformance and not o application(s).



		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
MA	C39	SIGAL, "Pitfalls in the Diagnosis and Management of Lyme Disease", 41 Arthritis & Rheumatism 195 (1998).	
	C40	SIGAL, "The Polymerase Chain Reaction Assay for Borrelia burgdorferi in the Diagnosis of Lyme Disease", 120 Annals Intern. Med. 520 (1994).	
	C41	SIGAL, "A Vaccine Consisting of Recombinant Borrelia burgdorferi Outer-Surface Protein A to Prevent Lyme Disease", 339 New Engl. J. Med. 216 (1998).	
	C42	SIMPSON, "Antibody to a 39-Kilodalton Borrelia burgdorferi Antigen (P39) as a Marker for Infection in Experimentally and Naturally Inoculated Animals", 29 J. Clin Microbiol 236 (1991).	
	C43	SIMPSON, "Nucleotide Sequence and Analysis of the Gene in Borrelia burgdorferi Encoding the Immunogenic P39 Antigen", 119 Fed of Europ. Microbiol. Soc.s Letters 381 (1994).	
	C44	SIMPSON, "Reactivity of Human Lyme Borreliosis Sera with a 39-Kilodalton Antigen Specific to Borrelia burgdorferi", 28 J. Clin Microbiol 1329 (1990).	
	C45	YU, "Multi-Well ELISA Based on Independent Peptide Antigens for Antibody Capture", 198 J. Immunol. Meth. 25 (1996).	
	C46	YU, "Presentation of Peptide Antigens as Albumin Conjugates for Use in Detection of Serum Antibodies by Enzyme-Linked Immunosorbent Assay", 7 Bioconjugate Chem. 338 (1996).	
	C47	ZALIPSKY, "Attachment of Drugs to Polyethylene Glycols", 19 Eur. Polym. J. 1177 (1983).	
	C48	ZALIPSKY, "Esterification of Polyethylene Glycols", A21 J Macromol. SciChem. 839 (1984).	\exists
	C49	ZALIPSKY, "Functionalized Poly(ethylene glycol) for Preparation of Biologically Relevant Conjugates", 6 Bioconjugate Chem. 150 (1995).	

EXAMINER	00	DATE CONSIDERED
G	Powart	10-1-04
*EXAMINER:	Initial if reference considered, whether or not criteria is in conform	nance with MPEP 609. Draw line through citation if not in conformance and not
	considered. Include copy of this form with next communication t	p application(s).